☒ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For
the fiscal year ended April 30, 2016

☐TRANSITION
REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For
the transition period from[ ] to [
]

Commission
file number 000-53376

ETERNITY
HEALTHCARE INC.

(Exact
name of registrant as specified in its charter)

Nevada

75-3268426

(State
or other jurisdiction of
incorporation or organization)

(I.R.S.
Employer
Identification No.)

8755
Ash Street, Suite 1, Vancouver, British Columbia, Canada

V6P
6T3

(Address
of principal executive offices)

(Zip
Code)

Registrant's
telephone number, including area code:(855) 324-1110

Securities
registered pursuant to Section 12(b) of the Act:

Title
of Each Class

Name
of Each Exchange On Which Registered

N/A

N/A

Securities
registered pursuant to Section 12(g) of the Act:

Common
Stock, Par Value of $0.001 Per Share

(Title
of class)

Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 the Securities Act. Yes ☐ No ☒

Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

Indicate
by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such
reports) and (2) has been subject to such filing requirements for the last 90 days. Yes ☒ No ☐

Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-K (§229.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).Yes ☒ No ☐

Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not
contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☐

Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See definition of “large accelerated filer,” “accelerated filer” and “smaller
reporting company” in Rule 12b-2 of the Exchange Act.

Large
accelerated filer

☐

Accelerated
filer

☐

Non-accelerated
filer

☐

Smaller
reporting company

☒

Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The
aggregate market value of Common Stock held by non-affiliates of the Registrant on October 30, 2015 was $869,979.25 based on a
$0.07 average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed
second fiscal quarter. On October 30, 2015 non-affiliates of the Registrant held 12,428,275 common shares.

Indicate
the number of shares outstanding of each of the registrant’s classes of common stock as of the latest practicable date.

This
annual report contains forward-looking statements. These statements relate to future events or our future financial performance.
In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expects”,
“plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”
or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions
and involve known and unknown risks, uncertainties and other factors, including the risks in the section entitled “Risk
Factors”, that may cause our or our industry’s actual results, levels of activity, performance or achievements to
be materially different from any future results, levels of activity, performance or achievements expressed or implied by these
forward-looking statements.

Although
we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results,
levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United
States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Our
consolidated financial statements are stated in United States Dollars (US$) and are prepared in accordance with United States
Generally Accepted Accounting Principles.

In
this annual report, unless otherwise specified, all dollar amounts are expressed in United States dollars and all references to
“common shares” refer to the common shares in our capital stock.

We
were incorporated in the State of Nevada on October 24, 2007. On September 23, 2010, we changed our name to Eternity Healthcare
Inc., and we effected a reverse split of our issued and outstanding common stock on a 10 old shares for 1 new share basis.

On
December 13, 2010 we entered into and completed a share exchange agreement with Eternity Healthcare Inc., a British Columbia corporation,
wherein we acquired Eternity BC as our wholly owned subsidiary and abandoned our former business to focus on the operations of
Eternity BC.

On
June 5, 2014 our company registered to operate within the state of Arizona with the intention to take over operations within the
United States from our Canadian subsidiary. Beginning January 1, 2016 our company took over operations within the United States
from Eternity Healthcare, Inc. (BC).

Our
Current Business

We
are a medical device company that, subject to government approval, plans to manufacture and market medical devices. Our first
product marketed was a needle-free injection system throughout the world. The products which market now and we hope to market
in the future differ from other current offerings by allowing ordinary people to perform injection of medication without the need
for professionals.

On
June 25, 2012, we entered into a marketing agreement to sell a device which does not require a needle for injection of medicine
to the body from Mika Medical Company of South Korea. They provided us with the exclusivity rights for this device throughout
North America, Germany, France and Spain and non-exclusive rights for the world market. In 2015, we decided to bring our own needle-free
injection device with superior technology and decided to market both products. We are currently non-exclusive marketer of the
Korean product.

1

Principal
Product

Currently,
our company is focused on a new needle-free injection device technology that our company is marketing. Our second product is an
over the counter pain treatment device using laser as treatment source. This product is currently under approval by the FDA in
the United States. The Company has additional technologies in the development stage. Our company plans to bring the additional
products to the market in next few years.

Needle-free
Injection System Applications

Diabetes
- It is estimated there are 50 million diabetics in North America with 8.3% of the total population actually diagnosed. Of
the diagnosed diabetic patients approximately 6 million patients (20%) are receiving insulin on a daily basis. The fear surrounding
their daily injection is needless; there is technology available to deliver the insulin below the skin that does not require a
needle. This option results in a soft injection system that is less painful and less intimidating.

Pediatric
Oncology – It is well known that children are horrified of the needle and as result sometime parents are giving up the
use of those drugs that has to be injected towards more oral drugs (though that is also horrible due to taste barrier), or go
for intravenous catheters. There are about 20 anti-cancer drugs are injectable that needle-free injection device can be used instead
of needle. Approximately 10 million children and adolescents receive injections annually.

MS
– Multiple sclerosis is a neurological disease affecting almost 400,000 people in the United States. Most patients receive
different forms of interferons under various brand names, which are injected subcutaneously on a daily basis. Needle-free injection
devices could be used for these people as they are tired of needle injection.

Growth
Hormones - Human growth hormone is used for children suffering from lack of growth height and various other conditions. Also,
growth hormones are used in adults for work performance, sport performance and losing fat, etc. The hormone which is presently
injected has been a cause of mental barrier for people. Needle-free injection devices should be an excellent choice for those
who do not like needle injections.

Anesthetics
– Local anesthetics such as lidocaine are used routinely for surface surgery, dental work and cosmetic playground. Patients
are unhappy to see needles going through their skin for desensitization, particularly those involving face or dental work. Needle-free
injection devices can deliver local anesthetic and pain killer conveniently. Over 20 million injections for local anesthetics
are performed annually.

Vaccine
- Vaccination involving a whole range of products is a major healthcare activity. Globally over 1 billion vaccinations of
different kinds are performed annually and it is estimated in the US to be about 20 million per annum. Some vaccines are given
subcutaneously, some intramuscularly and some intradermally. Most vaccination (about 90%) is carried out in children. Children
are not happy to receive needles for their vaccination. Needle-free injection devices will be a darling for vaccination of children.

Cardiovascular
- Death due to cardiovascular disease and stroke today surpasses the deaths due to cancer. There are approximately 30 million
deaths as result of cardiovascular failures in the US. Often oral medications fail to act due to the time which it requires a
drug to get from digestive organs to the blood. Injectable medications are clearly the better choice. Healthcare professionals
are always worried of self-contamination and other inconveniences. Use of Needle-free injection device for injecting cardiovascular
medication is highly appreciated.

Migraine
– Migraines, along certain sever pain conditions, are highly common among the adult population. A quick injection of
anti-migraine drugs or other sorts of pain killers, including opiates, are often used. Needles are not desirable tools for the
patients and these people prefer to use non-injections approach. Once again Needle-free injection devices can alleviate the inconveniences
of needles while providing similar benefits.

2

Market

Intended
and Current

Retail
Pharmacies

Currently,
the needle-free injectors are not available for sale to individuals. The pharmacists in various countries do not acknowledge a
demand for the product. There appears to be a complete lack of knowledge of these devices at the retail level.

Hospitals

Hospitals
contain trained professionals who are expected to handle sharps. The pricing model of the two modalities (needle/injector) will
need to be much closer together before hospitals agree to use injectors. The US hospital system lends itself well to new technologies
and this offers us a huge opportunity in that country.

Physician
Offices

Physicians
are looking for anything that saves them time. The needle-free injectors offer patients an option and may be considered in this
setting. Children have a high level of anxiety with needles.

Corrections

The
ability to remove sharps in correctional facilities is considered a major advantage.

Military

The
military tends to have mass injection programs and if the injectors can prove to reduce injection time, increase personnel safety
or reduce cost, it would be considered as a primary vehicle for vaccine injections.

Corporate
Health

This
is an upscale market that may appreciate the perceived benefit and advancement that injectors convey.

US
Public Health

Public
health clinics serve 87 million citizens in the United States and handle most of the immunization needs for these patients. Competitors,
such as PharmaJet, got their start in the public health arena in 2009 by providing needle-free injections for the broad H1N1 flu
shot campaign in the state of New Jersey. This led to interest from other locations, including Los Angeles County, which is standardizing
the PharmaJet needle-free system.

Cosmetic
Applications

There
may be opportunities with dermatologists, clinics and other health care professionals that perform plastic and/or other surgeries.

Veterinary
Medicine

There
are also applications for veterinary medicine. Currently, more robust “backpack” versions of injectors using hoses
are used with large animals/herds. A small unit of Needle-free injection device (with another brand name) may be useful in a local
veterinarian office. This can be investigated when resources and/or the market warrants the focus.

3

Conclusions:

●

The
needle-free market has advantages;

●

There
are specific areas where needle-free holds important advantages;

●

Professional
support will be crucial to success;

●

There
are many applications for needle-free technology, although each must be investigated and the largest payoff areas will be
attempted first.

Unintended
Markets:

It
appears that there are other groups of patients that may try to use the Needle-free injection device in areas it is not intended
for. Chat rooms for bodybuilders discuss various methods of steroid injection and needle-free technology is discussed. As we move
into the marketplace we need to be aware that the product may not be used according to manufacturer’s intentions. There
may also be applications around tattoo parlors and piercings.

Patient
Barriers to Needles

Increasing
demand for painless drug delivery will drive the growth of this market. The advent of biologics and biotechnology-based compounds
that need to be delivered using specialized delivery systems has also fueled the demand for innovative and effective delivery
devices. Needles have one advantage, cost. With increased demand for needle-free technology, new materials discovered and increased
production volumes, the costs will drop and that advantage will be lost.

Competition

Around
the world, needle-free jet injectors have an established market among diabetic patients. In the United States, more than a dozen
needle-free jet injectors have been licensed by the FDA and are on the professionals market. A few of these devices are being
used in physicians’ offices. The most competitive product to ours is Injex™ which is marketed both to professionals
and patients at a cost of $900. In Europe, needle-free injectors have become very popular with about 50% of insulin users utilizing
needle-free jet injectors. Currently, each manufacturer makes its own type of cartridge that holds the vaccine which is attached
to the device before injection.

AdvantaJet

The
AdvantaJet is in its 25th year of production. They claim a durable life-long device with clients still using the jet injector
after 20 years of use. They also claim they have studies and have shown increased efficacy over needle injections. Specifically:

●

It
is the most economical delivery system for insulin for all type 1 diabetics;

●

It
is the only system that provides a lifetime commitment to replace and repair the product;

●

It
is the most accurate delivery system providing the most precise dosage;

●

It
is the most comfortable system with the least skin abrasions and contusions.

They
offer a custom made jet that can be supplied to the patient’s specific needs. Changes to orifice design and power settings
decrease due to the increased absorption. There is no data to support this and it is interesting they discuss cost considering
the unit cost shown below.

Proven
Effective

AdvantaJet
injection technology was tested and determined to be an effective method of managing diabetes in both humans and companion animals.

4

Conclusions:

Price
reflects their attempt to be the best quality, proven injector.

Akra

Akra
is a French based company selling the brand Dermojet. They claim to be in over 90,000 physicians’ offices around the world.
They are squarely focused on the professional market. They have a very sleekly designed unit, almost surgical in its appearance.
Although this may deter the average consumer, the look of the unit must be very tempting to professionals. The unit can also be
sterilized; something an institutional setting would be interested in.

The
Dermojet is patented and in North America is exclusively distributed by Robbins Instruments. They claim it is the finest needleless
injection system available on the medical market today. “The innovative design and superior quality have made the Dermojet
renowned for its usefulness in many different types of procedures and disciplines.”.

Efficient:
Incorporated reservoir allows for operation in every position;

●

Easy
to use: The armament is activated by a simple turn of the lever, and the liquid is flushed by pressing the button on the upper
part of the machine.

Conclusions:

●

Price
reflects focus on professional market;

●

Specifically
designed for professional use.

Antares

Antares
Pharma is a pharmaceutical company that focuses on self-injection pharmaceutical products and technologies and topical gel-based
products. They have subcutaneous and intramuscular injection platforms that focus mostly on disposable, pressure assisted auto-injectors.
Their needle-free injection units are developed with pharmaceutical companies and tend to be product specific. Examples are human
growth hormones with Teva (Tjet), Ferring Pharmaceuticals (Zomajet), and JCR Pharmaceuticals (Twin-jector).

Antares
is based in Ewing, New Jersey and has a subsidiary in Switzerland. They were formerly known as Medi-Ject Corporation and acquired
the operating subsidiaries of Permatec Holding AG, headquartered in Basel, Switzerland. Medi-Ject was focused on delivering drugs
across the skin using needle-free technology, and Permatec specialized in delivering drugs across the skin using gel technologies
as well as developing oral disintegrating tablet technology. Upon completion of the transaction the name was changed to Antares
Pharma Inc. The Parenteral Products (device) group is located in Minneapolis where they develop and manufacture, with partners,
various novel pressure assisted injectors, with and without needles, which allow patients to self-inject drugs. They have entered
into multiple licenses for these devices mainly in the U.S. and Canada with Teva. Several licensing agreements with pharmaceutical
companies of various sizes have led to successful clinical evaluation of formulations.

5

The
kit included:

●

Medi-Jector
Vision Injector;

●

Injection
Supply Start-up Kit - 2 nozzles and 2 vial adapters;

●

Carrying
Case;

●

Instruction
Manual;

●

Training
Video.

Conclusions:

●

Antares
focuses on the larger market of needle-free that includes all modes of delivery;

●

They
have a successful track record of pharmaceutical collaboration;

●

They
have multiple office sites and abilities;

●

They
are aggressively pursuing markets both collaboratively and alone.

Zogenix

Zogenix
is a California based company that currently markets Sumavel DosePro. This is a needle-free delivery system that requires a prescription
and is used to treat adults who have been diagnosed with acute migraine or cluster headaches. Zogenix claims that DosePro is a
first-in-class, easy-to-use drug delivery system designed for self-administration of a pre-filled, single dose of liquid drug,
subcutaneously, without a needle. DosePro offers benefits to patients including instant, easy dosing, less anxiety over self-injection,
no need for sharps disposal, no risk of needle stick injury or contamination, and reliable performance.

Zogenix’s
lead investigative product is the Zohydro ER, which received FDA approval in October, 2013. It offers the benefit of less frequent
dosing and the ability to treat chronic pain patients without the risk of acetaminophen-related liver injury. The second investigational
product candidate they have is Relday, which is a combination of their DosePro needle-free system and a proprietary, subcutaneous,
once-monthly formulation of risperidone for the treatment of schizophrenia.

Conclusions:

●

Zogenix
is another successful player in this category;

●

Off
patent pharmaceuticals seem to get a new life with novel injector technologies;

●

A
lot of money can be raised in this area with a strong management team.

Inovio
Pharmaceuticals

Inovio
Pharmaceuticals entered the needless injector market through its acquisition of BioJect in March, 2016. BioJect was dedicated
to the improvement of delivery of pharmaceuticals and biologics through the development and commercialization of advanced needle-free
injection technologies and developed a broad platform technology for delivering injectable vaccines and medications using its
proprietary pressure profiles. This proprietary technology enables BioJect to provide needle-free injection systems which have
a greater range of capabilities than other available devices.

The
products as marketed are:

Biojector
2000 Needle-free Injection System

The
Biojector 2000 is a durable, professional-grade injection system designed for healthcare providers. They claim that it is the
only needle-free system in the world cleared by the FDA to deliver intramuscular injections. The system can also deliver subcutaneous
injections, and is being used for intradermal injections in clinical trials.

6

BioJect
ZetaJet

The
ZetaJet system consists of two components, the portable injector and an auto-disabling disposable syringe. It is intended to deliver
vaccines and injectable medications either subcutaneously or intramuscularly and is indicated for both professional use and home
use for patients who self-inject.

Conclusions:

●

The
products are similar to ours;

●

Inovio
is an established bio technology company.

BioValve

BioValve
Technologies, Inc. operates as a specialty pharmaceutical and drug delivery company engaging in the development and commercialization
of chemical entities for the treatment of conditions of the central nervous system. The company offers various dopamine agonists
for treatment of Parkinson’s disease and schizophrenia; and novel disposable pharmaceutical delivery systems. The company,
through its subsidiary, offers h-Patch and e-Patch controlled release disposable micro pump systems; Mini-Ject, a pre-filled needle-free
delivery system; and the Micro-Trans, a micro needle transdermal delivery patch. Its products provide insulin management for patients.
BioValve Technologies, Inc. is a private company and was founded in 1998. It is based in Parsippany, New Jersey with an additional
location in Westborough, Massachusetts.

Conclusions:

●

BioValve
is quite interesting as the principle is also involved with Valeritas;

●

They
focus on the bigger market of needle-free delivery, not just jet injectors.

Injex

Injex
Pharma AG is a wholly owned subsidiary of Paketeria AG as of December 16, 2011. It markets and sells the Injex 30 System worldwide.
The Injex 30 is a syringe without a needle used in multiple medical, cosmetic and anesthetic applications. It is interesting to
note that Injex is expanding into cosmetic and launching Shireen Beauty system focused on the rejuvenation of the skin. Fluid
is sprayed with high pressure within a small distance of the skin via a pore-jet allowing the fluid open access to pores contained
in the upper layers of the skin. Injex is casting as wide a market as possible targeting diabetes, local and dental anesthetics,
allergy and fertility treatments, vaccinations, veterinary use, erectile dysfunction and growth hormones.

Conclusions:

●

Injex
is expensive both the device and nozzles;

●

Injex
has an agreement for Canadian and US distribution;

●

Injex
should be an immediate competitor;

●

Injex
foray into beauty may hurt/help, further study is needed.

Pharmajet

Pharmajet
is based in Golden, Colorado. They are focused on a safer workplace, lower needle reuse, and to help children avoid needle anxiety.

Pharmajet
was founded by Kathy Callender who insisted her device be cost competitive with the cheapest needles. Her goal is that poor countries
can afford needle free technology but this has also led to the ability to underbid rivals to supply pharmaceutical companies.
She has raised $14 million from investors. In March 2011 Pharmajet completed unspecified B round financing. It seems their plan
is to build sales volume in the U.S. vaccination market through public-health departments and pharmacy chains, then among consumers
who self-inject at home; and doctor’s offices here and abroad. That way, PharmaJet expects to approach a production volume
of 50 million cartridges a year which would allow it to compete on a price level with needles in developing countries. Pharmajet
received FDA clearance last year for the use of their needle-free injection device for vaccination purposes.

7

Conclusions:

●

The
founder is a dedicated supporter of helping the third world;

●

The
focus on low cost has the ability to shrink the market if successful;

●

Zogenix
was quoted as saying they wouldn’t survive;

●

They
are not focused on pharmaceutical collaboration, however they have landed deals that focus on the goal of affordable expansion.

Crossject

Crossject
is a French company that successfully designs and develops innovative, needle-free, pre-filled, single-use injection systems for
intradermal, subcutaneous and intramuscular applications for pharmaceutical companies. They use their single technological platform
and offer exclusive partnerships to pharmaceutical companies in a given field or therapeutic class. Crossject is based in Paris
and has offices in Dijon. Crossject technology is the outcome of research and development cooperation initiated and developed
with industrial partners, each a European leader in its field.

The
Zeneo is made up of three distinct subassemblies: an actuator, a pharmaceutical subassembly and a nozzle. The actuator generates
sufficient pressure to inject the drug to the required depth beneath the skin, without the use of a needle. The platform can be
adapted to different pharmaceutical applications:

●

the
intensity of the gas generator and the nozzle can be adapted to ensure the proper penetration and optimal distribution of
the drug in the target tissue;

●

the
pharmaceutical subassembly can be aseptically filled on standard high-throughput syringe filling line;

●

To
date, Crossject has filed 26 patent family applications and holds over 370 patents granted worldwide.

Conclusions:

●

Crossject
is focused on the European market;

●

Crossject
has been successful with pharmaceutical collaborations;

●

Their
perceived lack of customization in the consumers’ eyes may turn off some potential partners.

Valeritas

Valeritas
develops and commercializes drug delivery solutions. The company focuses on the treatment of diabetes. Its products include V-Go,
a disposable insulin delivery device that provides a preset basal rate and on-demand bolus dosing for mealtime coverage. The company’s
products also include h-Patch for the delivery of various compounds; Mini-Ject pre-filled needle-free delivery system to deliver
drugs ranging from molecules to proteins, fragile antibodies, and vaccines; and Micro-Trans micro needle array patch technology
for drug delivery into the dermis. Valeritas, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey. The Mini-Ject
is manufactured under Biovalve and these two companies are both linked privately.

Conclusions:

●

Valeritas
has synergy with BioValve;

●

Valeritas
has been successful in collaborations with drug companies;

●

Valeritas
has the ability to provide other novel drug delivery products.

8

Penjet

It
is a single use, disposable jet injector that comes prefilled with the proper drug dose. It can be administered in a few seconds
by a care giver or the patient themselves.

This
company is not found on the partial list of needle-free injectors and was added as an example of how many other manufacturers
there are. This has led to the conclusions below.

Competitive
Landscape Conclusions

Antares
cites as competition, The Medical House plc. Medical House developed the Cool.clickTM2 needle-free injector for Merck Serono.
However it had revenue results for the year ended April 30, 2012 of £1.4 million (USA $2,169,197) representing a growth
by 25%. They are included here as an example of the many niche companies that are pairing up with pharmaceutical companies.

There
is also competition from internal groups within large pharmaceutical companies and various design houses which complete the design
of devices for companies but don’t have manufacturing management capabilities. There are a number of companies that are
relatively inactive, focused on peripheral markets or concentrated on certain geographic areas.

This
leaves us with our perceived competitors at launch. Our company will focus on diabetes and begin forging alliances to strategically
place itself squarely in this area.

Government
Regulations

Government
authorities in the United States and Canada, at the federal, state and local levels, and other countries extensively regulate,
among other things, the research, development, testing, manufacturing, labeling, promotion, advertising, distribution, marketing
and export and import of medical devices such as needle-free injection systems. The process of obtaining regulatory approvals
and the subsequent substantial compliance with appropriate federal, state, local and foreign statutes and regulations require
the expenditure of substantial time and financial resources.

9

We
are required to obtain two sets of license for the sale and marketing of medical devices. In Canada, as in the United States and
Europe, needle-free injection systems are classified as medical devices and require the following licenses: 1) Product License;
and 2) Establishment License.

Product
License: Needle-free injection systems are classified internationally as Class I or II and in the United States are subject to
510-k regulatory filing fee.

Description
of Different Classes

Class
I includes products of which several examples are already approved and marketed in Canada or USA. As long as the basic science
remains the same, the application for approval of a new product is straight forward. One product in this category would be a pregnancy
test or regular needle/syringes.

Class
II products are those which do not need to be injected (the device itself) or inserted into the patient (non-invasive). Often
these products are approved and sold throughout the world. The products which we are currently focusing on distributing all belong
to Class II. In order to secure the necessary license for these products, we are required to submit all the documentation which
will lead to the approval of the products in other countries. In our case, our products are already approved in Europe, Canada,
etc. As far as for FDA compliance is concerned, we are required to submit all of the scientific data, results, approval process
and certificates of good quality management pursuant to ISO 13485 and ISO 21649-2006. Usually, products which have the ISO accreditation
and CE Mark easily obtain FDA approval.

Environmental
Regulations

We
are not aware of any material violations of environmental permits, licenses or approvals that have been issued with respect to
our operations. We expect to comply with all applicable laws, rules and regulations relating to our business, and at this time,
we do not anticipate incurring any material capital expenditures to comply with any environmental regulations or other requirements.

While
our intended projects and business activities do not currently violate any laws, any regulatory changes that impose additional
restrictions or requirements on us or on our potential customers could adversely affect us by increasing our operating costs or
decreasing demand for our products or services, which could have a material adverse effect on our results of operations.

Employees

As
of April 30, 2016 we had two full time employees and two consultants, working on our business. We plan (within next twelve months)
to hire one new full-time employee and one additional consultant to work for us on marketing, distribution, commercialization
of our products.

REPORTS
TO SECURITY HOLDERS

We
are required to file annual, quarterly and current reports, proxy statements and other information with the Securities and Exchange
Commission and our filings are available to the public over the internet at the Securities and Exchange Commission’s website
at http://www.sec.gov. The public may read and copy any materials filed by us with the Securities and Exchange Commission at the
Securities and Exchange Commission’s Public Reference Room at 100 F Street N.E. Washington D.C. 20549. The public may obtain
information on the operation of the Public Reference Room by calling the Securities and Exchange Commission at 1-800-732-0330.
The SEC also maintains an Internet site that contains reports, proxy and formation statements, and other information regarding
issuers that file electronically with the SEC, at http://www.sec.gov.

10

Item 1A.

Risk Factors

Much
of the information included in this annual report includes or is based upon estimates, projections or other “forward looking
statements”. Such forward looking statements include any projections and estimates made by us and our management in connection
with our business operations. While these forward-looking statements, and any assumptions upon which they are based, are made
in good faith and reflect our current judgment regarding the direction of our business, actual results will almost always vary,
sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested herein.

Such
estimates, projections or other “forward looking statements” involve various risks and uncertainties as outlined below.
We caution the reader that important factors in some cases have affected and, in the future, could materially affect actual results
and cause actual results to differ materially from the results expressed in any such estimates, projections or other “forward
looking statements”.

Risks
Related to Our Business

We
have a history of losses and a limited history of revenues, which raise substantial doubt about our ability to continue as a going
concern.

From
inception to April 30, 2016, we have incurred aggregate net losses of $2,110,822. We can offer no assurance that we will ever
operate profitably or that we will generate positive cash flow in the future. In addition, our operating results in the future
may be subject to significant fluctuations due to many factors not within our control, such as the unpredictability of when customers
will order products, the size of customers’ orders, the demand for our products, and the level of competition and general
economic conditions.

Our
company’s operations will be subject to all the risks inherent in the establishment of a developing enterprise and the uncertainties
arising from the absence of a significant operating history. No assurance can be given that we may be able to operate on a profitable
basis.

Due
to the nature of our business and the early stage of our development, our securities must be considered highly speculative. We
have not realized a profit from our operations to date and there is little likelihood that we will realize any profits in the
short or medium term. Any profitability in the future from our business will be dependent upon the successful commercialization
or licensing of our core products, which themselves are subject to numerous risk factors as set forth below.

We
expect to continue to incur development costs and operating costs. Consequently, we expect to incur operating losses and negative
cash flows until our products gain market acceptance sufficient to generate a commercially viable and sustainable level of sales,
and/or additional products are developed and commercially released and sales of such products made so that we are operating in
a profitable manner. Our history of losses and limited history of revenues raise substantial doubt about our ability to continue
as a going concern.

We
have had negative cash flows from operations since inception. We will require significant additional financing, the availability
of which cannot be assured, and if our company is unable to obtain such financing, our business may fail.

To
date, we have had negative cash flows from operations and have depended on sales of our equity securities and debt financing to
meet our cash requirements. We may continue to have negative cash flows. We have estimated that we will require approximately
$500,000 to carry out our business plan for the next twelve months. There is no assurance that actual cash requirements will not
exceed our estimates. We will require additional financing to finance working capital and pay for operating expenses and capital
requirements until we achieve a positive cash flow.

11

Our
ability to market and sell our medical devices will be dependent upon our ability to raise significant additional financing. If
we are unable to obtain such financing, we will not be able to fully develop our business. Specifically, we will need to raise
additional funds to:

●

Support
our planned growth and carry out our business plan;

●

Hire
top quality personnel for all areas of our business; and

●

Address
competing technological and market developments.

We
may not be able to obtain additional equity or debt financing on acceptable terms as required. Even if financing is available,
it may not be available on terms that are favorable to us or in sufficient amounts to satisfy our requirements. Any additional
equity financing may involve substantial dilution to our then existing shareholders. If we require, but are unable to obtain,
additional financing in the future, we may be unable to implement our business plan and our growth strategies, respond to changing
business or economic conditions, withstand adverse operating results and compete effectively. More importantly, if we are unable
to raise further financing when required, we may be forced to scale down our operations and our ability to generate revenues may
be negatively affected.

We
have a limited operating history and if we are not successful in continuing to grow our business, then we may have to scale back
or even cease our ongoing business operations.

We
have a limited history of revenues from operations and have no significant tangible assets. We have yet to generate positive earnings
and there can be no assurance that we will ever operate profitably. Accordingly, we must be considered in the development stage.
Our success is significantly dependent on a successful commercialization of our products. Our operations will be subject to all
the risks inherent in the establishment of a developing enterprise and the uncertainties arising from the absence of a significant
operating history. We may be unable to develop a successful product or achieve commercial acceptance of our product or operate
on a profitable basis. We are in the development stage and potential investors should be aware of the difficulties normally encountered
by enterprises in the development stage. If our business plan is not successful, and we are not able to operate profitably, investors
may lose some or all of their investment in our company.

If
we fail to effectively manage the growth of our company and the commercialization of our product, our future business results
could be harmed and our managerial and operational resources may be strained.

As
we proceed with the commercialization of our product and the expansion of our marketing and commercialization efforts, we expect
to experience significant growth in the scope and complexity of our business. We will need to add staff to market our services,
manage operations, handle sales and marketing efforts and perform finance and accounting functions. We anticipate that we will
be required to hire a broad range of additional personnel in order to successfully advance our operations. This growth is likely
to place a strain on our management and operational resources. The failure to develop and implement effective systems, or to hire
and retain sufficient personnel for the performance of all of the functions necessary to effectively service and manage our potential
business, or the failure to manage growth effectively, could have a material adverse effect on our business and financial condition.

Our
by-laws contain provisions with respect to the indemnification of our officers and directors against all expenses, liability and
loss (including attorneys’ fees, judgments, fines and amounts paid or to be paid in settlement) reasonably incurred or suffered
by him or her in connection with any action, suit or proceeding to which they were made parties by reason of his or her being
or having been one of our directors or officers.

Risks
Related to Our Common Stock

A
decline in the price of our common stock could affect our ability to raise further working capital, it may adversely impact our
ability to continue operations and we may go out of business.

A
prolonged decline in the price of our common stock could result in a reduction in the liquidity of our common stock and a reduction
in our ability to raise capital. Because we may attempt to acquire a significant portion of the funds we need in order to conduct
our planned operations through the sale of equity securities, a decline in the price of our common stock could be detrimental
to our liquidity and our operations because the decline may cause investors to not choose to invest in our stock. If we are unable
to raise the funds we require for all of our planned operations, we may be forced to reallocate funds from other planned uses
and may suffer a significant negative effect on our business plan and operations, including our ability to develop new products
and continue our current operations. As a result, our business may suffer and not be successful and we may go out of business.
We also might not be able to meet our financial obligations if we cannot raise enough funds through the sale of our common stock
and we may be forced to go out of business.

12

If
we issue additional shares in the future, it will result in the dilution of our existing shareholders.

We
are authorized to issue up to 300,000,000 shares of common stock with a par value of $0.001. Our board of directors may choose
to issue some or all of such shares to acquire one or more businesses or to provide additional financing in the future. The issuance
of any such shares will result in a reduction of the book value and market price of the outstanding shares of our common stock.
If we issue any such additional shares, such issuance will cause a reduction in the proportionate ownership and voting power of
all current shareholders. Further, such issuance may result in a change of control of our company.

Trading
of our stock may be restricted by the Securities Exchange Commission's penny stock regulations, which may limit a stockholder's
ability to buy and sell our stock.

The
Securities and Exchange Commission has adopted regulations which generally define "penny stock" to be any equity security
that has a market price (as defined) less than $5.00 per share or an exercise price of less than $5.00 per share, subject to certain
exceptions. Our securities are covered by the penny stock rules, which impose additional sales practice requirements on broker-dealers
who sell to persons other than established customers and "accredited investors". The term "accredited investor"
refers generally to institutions with assets in excess of $5,000,000 or individuals with a net worth in excess of $1,000,000 or
annual income exceeding $200,000 or $300,000 jointly with their spouse. The penny stock rules require a broker-dealer, prior to
a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document in a form
prepared by the Securities and Exchange Commission, which provides information about penny stocks and the nature and level of
risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offer quotations for the
penny stock, the compensation of the broker-dealer and its salesperson in the transaction and monthly account statements showing
the market value of each penny stock held in the customer's account. The bid and offer quotations, and the broker-dealer and salesperson
compensation information, must be given to the customer orally or in writing prior to effecting the transaction and must be given
to the customer in writing before or with the customer's confirmation. In addition, the penny stock rules require that prior to
a transaction in a penny stock not otherwise exempt from these rules, the broker-dealer must make a special written determination
that the penny stock is a suitable investment for the purchaser and receive the purchaser's written agreement to the transaction.
These disclosure requirements may have the effect of reducing the level of trading activity in the secondary market for the stock
that is subject to these penny stock rules. Consequently, these penny stock rules may affect the ability of broker-dealers to
trade our securities. We believe that the penny stock rules discourage investor interest in and limit the marketability of our
common stock.

FINRA
sales practice requirements may also limit a stockholder's ability to buy and sell our stock.

In
addition to the "penny stock" rules described above, the Financial Industry Regulatory Authority (FINRA), formerly the
National Association of Securities Dealers or NASD, has adopted rules that require that in recommending an investment to a customer,
a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending
speculative low priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain
information about the customer's financial status, tax status, investment objectives and other information. Under interpretations
of these rules, the FINRA believes that there is a high probability that speculative low priced securities will not be suitable
for at least some customers. The FINRA requirements make it more difficult for broker-dealers to recommend that their customers
buy our common stock, which may limit your ability to buy and sell our stock and have an adverse effect on the market for our
shares.

13

Item 1B.

Unresolved Staff Comments

As
a “smaller reporting company”, we are not required to provide the information required by this Item.

Item 2.

Properties

We
currently rent a warehouse and an assembly space of about 2,000 square feet at 8755 Ash Street, Suite 1, Vancouver, British Columbia,
Canada, V6P 6T3. Our office is also in the same location. Effective March 1, 2016, we are required to pay CAD $2,705 (USD $2,158)
plus applicable GST per month for rent. The original term of our lease was for a period of one year. We are currently renting
this space month-to-month.

Item 3.

Legal Proceedings

We
know of no material, existing or pending legal proceedings against our company, nor are we involved as a plaintiff in any material
proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered
or beneficial stockholder, is an adverse party or has a material interest adverse to our interest.

Our
common stock is not traded on any exchange. Our common stock is quoted on the OTC Markets under the trading symbol “ETAH”.
We cannot assure you that there will be a market in the future for our common stock.

OTC
Market securities are not listed and traded on the floor of an organized national or regional stock exchange. Instead, OTC Market
securities transactions are conducted through a telephone and computer network connecting dealers. OTC Market issuers are traditionally
smaller companies that do not meet the financial and other listing requirements of a national or regional stock exchange.

The
following table reflects the high and low bid information for our common stock obtained from Stockwatch and reflects inter-dealer
prices, without retail mark-up, markdown or commission, and may not necessarily represent actual transactions.

The
high and low bid prices of our common stock for the periods indicated below are as follows:

OTC Markets

Quarter Ended

High

Low

April 30, 2016

$

0.04

$

0.01

January 31, 2016

$

0.07

$

0.02

October 31, 2015

$

0.08

$

0.025

July 31, 2015

$

0.18

$

0.02

April 30, 2015

$

0.06

$

0.03

January 31, 2015

$

0.11

$

0.03

October 31, 2014

$

0.301

$

0.025

July 31, 2014

$

0.2999

$

0.10

April 30, 2014

$

1.17

$

0.2021

14

As
of July 20, 2016, there were approximately 21 holders of record of our common stock. As of such date, 66,429,868 common shares
were issued and outstanding.

We
have not paid any cash dividends on our common stock and have no present intention of paying any dividends on the shares of our
common stock. Our current policy is to retain earnings, if any, for use in our operations and in the development of our business.
Our future dividend policy will be determined from time to time by our board of directors.

Equity
Compensation Plan

On
January 15, 2013, our directors approved the adoption of the 2013 Stock Option Plan which permits our company to issue up to 6,300,000
shares of our common stock to directors, officers, employees and consultants of our company upon the exercise of stock options
granted under the 2013 Stock Option Plan.

The
following table summarizes certain information regarding our equity compensation plans as at April 30, 2016:

Plan category

Number of securities to

be issued upon exercise

of outstanding options,

warrants and rights

(a)

Weighted-average

exercise price of

outstanding options,

warrants and rights

(b)

Number of securities

remaining available for

future issuance under equity

compensation plans

(excluding securities

reflected in column (a))

(c)

Equity compensation plans approved by security holders

Nil

Nil

Nil

Equity compensation plans not approved by security holders

200,000

(1)

$

0.80

6,100,000

Total

200,000

$

0.80

6,100,000

(1)

Includes
100,000 unexercised stock options issued on January 15, 2013 and 100,000 unexercised
stock options issued on January 18, 2013.

Convertible
Securities

As
of April 30, 2016, we had outstanding options to purchase 200,000 shares of our common stock exercisable at $0.80.

On
January 15, 2013 our director, Bin Huang, was granted 100,000 stock options exercisable at a price of $0.80 per share for a period
of five years from the date of grant. The vesting schedules for the stock options are 12,500 options every quarter from January
15, 2013.

15

On
January 18, 2013 our director, Dominique F. Borrelly, was granted 100,000 stock options exercisable at a price of $0.80 per share
for a period of five years from the date of grant. The vesting schedules for the stock options are 12,500 options every quarter
from January 18, 2013.

Recent
Sales of Unregistered Securities; Use of Proceeds from Registered Securities

We
did not sell any equity securities which were not registered under the Securities Act during the year ended April 30, 2016
that were not otherwise disclosed on our quarterly reports on Form 10-Q or our current reports on Form 8-K filed during the year
ended April 30, 2016.

Purchase
of Equity Securities by the Issuer and Affiliated Purchasers

We
did not purchase any of our shares of common stock or other securities during our fourth quarter of our fiscal year ended April
30, 2016.

Item 6.

Selected Financial Data

As
a “smaller reporting company”, we are not required to provide the information required by this Item.

Item 7.

Management’s Discussion and Analysis of Financial
Condition and Results of Operations

The
following discussion should be read in conjunction with our audited financial statements and the related notes for the years ended
April 30, 2016 and April 30, 2015 that appear elsewhere in this annual report. The following discussion contains forward-looking
statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the
forward looking statements. Factors that could cause or contribute to such differences include, but are not limited to those discussed
below and elsewhere in this annual report, particularly in the section entitled "Risk Factors" beginning on page 11
of this annual report.

Our
audited financial statements are stated in United States Dollars and are prepared in accordance with United States Generally Accepted
Accounting Principles.

Purchase
of Significant Equipment

We
do not intend to buy any significant equipment over the next twelve months.

Personnel
Plan

We
plan to hire one new full-time employee and one additional consultant to work on marketing, distribution, commercialization and
regulatory approvals our products in the next 12 months.

Results
of Operations

For
the Year Ending April 30, 2016 and 2015

Year Ended

April 30,

2016

2015

Revenue

$

84,202

$

61,202

Cost of goods sold

$

34,050

$

21,274

Operating expenses

$

393,541

$

531,005

Net loss

$

(388,622

)

$

(507,492

)

16

Expenses

Our
operating expenses for our years ended April 30, 2016 and 2015 are outlined in the table below:

Year Ended

April 30,

2016

2015

General and administrative

$

92,728

$

101,471

Professional fees

$

37,882

$

65,237

Research and Development

$

110,792

$

115,498

Salaries

$

152,139

$

248,799

Our
financial statements report a net loss of $388,622 for the twelve month period ended April 30, 2016 compared to a net loss of
$507,492 for the twelve month period ended April 30, 2015. Our losses have decreased by $118,870 primarily as a result of a reduction
in operating expenses.

Operating
expenses for year ended April 30, 2016 decreased by $137,464 as compared to the comparative period in 2015 primarily as a result
of a decrease in salaries as a result of reduced salaries and executive compensation.

Revenue

We
have earned $216,115 in revenue since our inception on December 10, 2009.

Liquidity
and Financial Condition

Working
Deficit

At

April 30,

At

April 30,

2016

2015

Current Assets

$

618,618

$

955,052

Current Liabilities

$

1,134,831

$

1,072,216

Working Capital (deficit)

$

(516,213

)

$

(117,164

)

Our
total current liabilities as of April 30, 2016 were $1,134,831 as compared to total current liabilities of $1,072,216 as of April
30, 2015. The increase was primarily due to an increase in amounts due to related parties. During the year our company received
proceeds of $502,137 from related parties and made repayments of $471,459. As at April 30, 2016 our company had short-term investments
of $320,584 compared to $501,838 as at April 30, 2015.

Cash
Flows

Year Ended

April 30,

Year Ended

April 30,

2016

2015

Net Cash Used In Operating Activities

$

(325,118

)

$

(391,673

)

Net Cash Provided By Investing Activities

$

154,635

$

(521,590

)

Net Cash Provided by Financing Activities

$

30,678

$

937,989

Effect of Rates on Cash

$

(15,302

)

$

(14,182

)

Increase (Decrease) in Cash During the Period

$

(155,107

)

$

10,544

17

Operating
Activities

Net
cash used in operating activities was $325,118 for the year ended April 30, 2016 compared with net cash used in operating activities
of $391,673 in the same period in 2015. The decrease in cash used was primarily a result of decreased inventory purchases during
the year.

Investing
Activities

Net
cash provided by investing activities was $154,635 for the year ended April 30, 2016 compared to net cash used in investing activities
of $521,590 in the same period in 2015. The increase in case provided by investing activities is due to our company withdrawing
CAD $200,000 from our GIC and interest received of CAD $770.

Financing
Activities

Net
cash provided by financing activities was $30,678 for the year ended April 30, 2016 compared to $937,989 in financing activities
in the same period in 2015. The decrease is a result of a reduction of proceeds received from related parties in 2016.

Anticipated
Cash Requirements

We
have sufficient funds to complete our development and marketing plans. We do not believe that we need to raise any capital to
finance our operations.

Future
Financings

We
believe we do not require any additional financing. We believe with the funds currently on hand and the revenue generated from
the sale of our product, it should be sufficient to continue our operation.

Contractual
Obligations

As
a “smaller reporting company”, we are not required to provide tabular disclosure obligations.

Going
Concern

If
our operations and cash flow improve, management believes that we can continue to operate well into the future. However, no assurance
can be given that management's actions will result in profitable operations or an improvement in our liquidity situation. The
threat of our ability to continue as a going concern will cease to exist only when our revenues have reached a level able to sustain
our business operations.

Off-Balance
Sheet Arrangements

We
have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial
condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital
resources that is material to stockholders.

Critical
Accounting Policies

The
discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements,
which have been prepared in accordance with the accounting principles generally accepted in the United States of America. Preparing
financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities,
revenue, and expenses. These estimates and assumptions are affected by management’s application of accounting policies.
We believe that understanding the basis and nature of the estimates and assumptions involved with the following aspects of our
financial statements is critical to an understanding of our financial statements.

18

Principles
of Consolidation

The
consolidated financial statements include the accounts of our company and its wholly-owned subsidiary, Eternity Healthcare Inc.
(B.C.). All significant intercompany balances and transactions have been eliminated in consolidation.

Cash
and Cash Equivalents

Cash
and cash equivalents include highly liquid investments with original maturities of three months or less.

Inventory

Inventory
is stated at the lower of cost or market with cost determined under the weighted average cost method.

Revenue

Revenue
is recognized at the point of sale and includes shipping revenue for delivery to the purchaser. Total revenues do not include
sales taxes as we serve as a pass-through conduit for collecting and remitting sales taxes. We recognize retail sales returns
as they occur as historical returns have been negligible.

Foreign
Currency Translation

Our
company’s functional currency is the Canadian dollar and reporting currency is the U.S. dollar. All transactions initiated
in other currencies are translated into the reporting currency in accordance with ASC 830, “Foreign Currency Matters”
as follows:

i)

Assets
and liabilities at the rate of exchange in effect at the balance sheet date; and

ii)

Revenue
and expense items at rate of exchange at the dates on which those elements are recognized.

At
April 30, 2016, 1 United States dollar was equal to 1.2536 Canadian dollars (April 30, 2015 - 1.2064). The average rate of exchange
for the year ended April 30, 2016 was 1.3163 (April 30, 2015 - 1.1503).

Gains
and losses on translation are included in other comprehensive income (loss) in stockholders’ deficiency for the period.

Fair
Value

The
carrying value of cash and cash equivalents, accounts receivable, accounts payable and due to related parties approximate their
fair values because of the short-term maturity of these financial instruments.

Interest
Rate Risk

Our
company is not exposed to significant interest rate risk due to the short-term maturity of its monetary assets and liabilities.

Credit
Risk

Credit
risk is the risk of loss associated with counterparty’s inability to fulfill its payment obligations. Our company’s
credit risk is primarily attributable to cash and accounting receivable. Management believes that the credit risk concentration
with respect to financial instruments included in cash and accounts receivable is remote.

19

Currency
Risk

Our
company’s operating expenses are primarily incurred in Canadian dollars, and fluctuation of the Canadian dollar in relation
to the United States dollar will have an impact upon the profitability of our company and may also have an effect of the value
of our company’s. Our company has not entered into any agreements or purchased any instruments to hedge possible currency
risk. At April 30, 2016, 1 United States dollar was equal to 1.2536 Canadian dollars.

Basic
and Diluted Net Income (Loss) Per Share

Our
company computes net income (loss) per share in accordance with ASC 260, “Earnings per Share”. ASC 260 requires presentation
of both basic and diluted earnings per share (“EPS”) on the face of the income statement. Basic EPS is computed by
dividing net income (loss) available to common stockholders (numerator) by the weighted average number of shares outstanding (denominator)
during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury
stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price
for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants.
Diluted EPS excluded all dilutive potential shares if their effect is anti-dilutive.

Income
Taxes

Deferred
income taxes are reported for timing differences between items of income or expense reported in the financial statements and those
reported for income tax purposes in accordance with ASC 740, “Income Taxes”, which requires the use of the asset/liability
method of accounting for income taxes. Deferred income taxes and tax benefits are recognized for the future tax consequences attributable
to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases,
and for tax losses and credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Our company
provides for deferred taxes for the estimated future tax effects attributable to temporary differences and carry-forwards when
realization is more likely than not.

Comprehensive
Loss

ASC
22, “Comprehensive Income”, establishes standards for the reporting and display of comprehensive loss and its components
in the financial statements. As at April 30, 2016, our company has items that represent a comprehensive income (loss) and, therefore,
have included a schedule of comprehensive income (loss) in the financial statements.

Use
of Estimates

The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect
the amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements
and the reported amounts of revenues and expenditures during the reporting period. Actual results could differ from these estimates.

Segments
of an Enterprise and Related Information

ASC
280, “Segment Reporting” establishes guidance for the way that public companies report information about operating
segments in annual financial statements and requires reporting of selected information about operating segments in interim financial
statements issued to the public. It also establishes standards for disclosures regarding products and services, geographic areas
and major customers. ASC 280 defines operating segments as components of a company about which separate financial information
is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing
performance. Our company has evaluated this Codification and does not believe it is applicable at this time.

Recent
Accounting Pronouncements

Our
company does not expect the adoption of any other recent accounting pronouncements to have a material impact on our financial
statements.

Item 7A.

Quantitative and Qualitative Disclosures about Market
Risk

As
a “smaller reporting company”, we are not required to provide the information required by this Item.

Item 8.

Financial Statements and Supplementary Data

20

Eternity
Healthcare, Inc.

Consolidated
Financial Statements

Years
ended April 30, 2016 and 2015

(Expressed
in U.S. Dollars)

21

REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To
the Board of Directors and Shareholders of

Eternity
Healthcare, Inc.

We
have audited the accompanying consolidated balance sheets of Eternity Healthcare, Inc. as of April 30, 2016 and 2015, and the
related statements of operations and comprehensive loss, stockholders’ equity (deficit), and cash flows for each of the
years in the two year period ended April 30, 2016. These financial statements are the responsibility of the Company’s management.
Our responsibility is to express an opinion on these financial statements based on our audit.

We
conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are
free of material misstatement. The company is not required to have, nor were we engaged to perform, an audit of its internal control
over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing
audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness
of the company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes
examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting
principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.

In
our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Eternity
Healthcare, Inc. as of April 30, 2016, and the results of its operations and its cash flows for each of the years in the two year
period ended April 30, 2016, in conformity with accounting principles generally accepted in the United States of America.

The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed
in Note 2 to the financial statements, the Company has suffered net losses since inception and has accumulated a significant deficit.
These factors raise substantial doubt about its ability to continue as a going concern. Management’s plans in regard to
these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result
from the outcome of this uncertainty.

/s/
Sadler, Gibb & Associates, LLC

Salt
Lake City, UT

July
20, 2016

F-1

Eternity
Healthcare, Inc.

Consolidated
Balance Sheets

(Expressed
in U.S. Dollars)

April 30,

April 30,

2016

2015

$

$

Assets

Current assets

Cash and cash equivalents

259,040

414,147

Short-term investments (Note 4)

320,584

501,838

Accounts receivable

-

1,166

Prepaid expenses

32,593

3,000

GST/HST receivable

3,337

1,191

Inventory (Note 5)

3,064

33,710

Total current assets

618,618

955,052

Liabilities

Current liabilities

Accounts payable and accrued liabilities (Note 6)

156,944

150,989

Due to related parties (Note 7)

977,887

921,227

Total current liabilities

1,134,831

1,072,216

Shareholders’ equity (deficit)

Capital stock (Note 8)

Authorized

300,000,000 common shares, par value $0.001

Issued and outstanding

April 30, 2016 - 66,429,868 common shares

April 30, 2015 - 66,429,868 common shares

66,430

66,430

Additional paid-in capital

1,539,591

1,539,591

Accumulated other comprehensive gain (loss)

(11,412

)

(985

)

Accumulated deficit

(2,110,822

)

(1,722,200

)

Total stockholders’ equity (deficit)

(516,213

)

(117,164

)

Total liabilities and stockholders’ equity (deficit)

618,618

955,052

The
accompanying notes are an integral part of these consolidated financial statements.

F-2

Eternity
Healthcare, Inc.

Consolidated
Statements of Operations and Comprehensive Loss

(Expressed
in U.S. Dollars)

Year ended

Year ended

April 30,
2016

April 30,
2015

$

$

Sales

Product sales

84,202

61,202

Cost of goods sold

34,050

21,274

Gross profit

50,152

39,928

Operating expenses

General and administrative

92,728

101,471

Professional fees

37,882

65,237

Research and development

110,792

115,498

Salaries

152,139

248,799

Total operating expenses

393,541

531,005

Loss from operations

(343,389

)

(491,077

)

Other income (expense)

Interest income

3,685

5,209

Interest expense

(48,918

)

(21,624

)

Total other income (expense)

(45,233

)

(16,415

)

Net loss

(388,622

)

(507,492

)

Comprehensive loss

Net loss

(388,622

)

(507,492

)

Foreign currency translation adjustments

(10,427

)

17,218

Comprehensive loss

(399,049

)

(490,274

)

Comprehensive loss per share - basic and diluted

(0.01

)

(0.01

)

Net loss per share - basic and diluted

(0.01

)

(0.01

)

Weighted average number of common shares Outstanding - basic and diluted

66,429,868

66,373,238

The
accompanying notes are an integral part of these consolidated financial statements.

F-3

Eternity
Healthcare, Inc.

Consolidated
Statements of Stockholders’ Equity (deficit)

(Expressed
in U.S. Dollars)

Amount

Additional

Accumulated

Accumulated

Number

($0.001 par)

paid-in capital

OCI

deficit

Total

of shares

$

$

$

$

$

Balance as at April 30, 2014

66,299,868

66,300

1,500,679

(18,203

)

(1,214,708

)

334,068

Common stock issued for services

130,000

130

8,970

-

-

9,100

Fair value of option vested

-

-

29,942

-

-

29,942

Currency translation adjustments

-

-

-

17,218

-

17,218

Net loss for the year ended April 30, 2015

-

-

-

-

(507,492

)

(507,492

)

Balance as at April 30, 2015

66,429,868

66,430

1,539,591

(985

)

(1,722,200

)

(117,164

)

Currency translation adjustments

-

-

-

(10,427

)

-

(10,427

)

Net loss for the year ended April 30, 2016

-

-

-

-

(388,622

)

(388,622

)

Balance as at April 30, 2016

66,429,868

66,430

1,539,591

(11,412

)

(2,110,822

)

(516,213

)

The
accompanying notes are an integral part of these consolidated financial statements

F-4

Eternity
Healthcare, Inc.

Consolidated
Statements of Cash Flows

(Expressed
in U.S. Dollars)

Year ended

Year ended

April 30,
2016

April 30,
2015

$

$

Operating activities

Net loss

(388,622

)

(507,492

)

Adjustments to reconcile net loss to net cash used in operating activities

Expenses paid on behalf of the Company by related parties

7,334

287

Fair value of stock options vested

-

29,942

Stock issued for services

-

9,100

Changes in operating assets and liabilities

Prepaid expenses and other current assets

(28,383

)

(5,118

)

Accounts payable and accrued liabilities

59,877

94,124

Accounts receivable

(920

)

(1,129

)

Inventory

25,596

(11,387

)

Net cash used in operating activities

(325,118

)

(391,673

)

Investing activity

Short-term investments

154,635

(521,590

)

Net cash provided by investing activities

154,635

(521,590

)

Financing activities

Proceeds from related party payables

502,137

1,210,105

Repayments on related party payables

(471,459

)

(272,117

)

Net cash provided by financing activities

30,678

937,989

Effect of exchange rate changes on cash

(15,302

)

(14,182

)

Increase (decrease) in cash

(155,107

)

10,544

Cash, beginning of year

414,147

403,603

Cash, end of year

259,040

414,147

The
accompanying notes are an integral part of these consolidated financial statements

F-5

Eternity
Healthcare, Inc.

Notes
to the Consolidated Financial Statements

April
30, 2016 and 2015

(Expressed
in U.S. Dollars)

1.

Nature and continuance of operations

Eternity
Healthcare Inc. (the “Company”) was incorporated under the laws of the State of Nevada on October 24, 2007 under the
name Kid’s Book Writer, Inc. On September 23, 2010, the Company changed its name to Eternity Healthcare Inc., and affected
a reverse stock split of the issued and outstanding common stock at a factor of 10 old shares for 1 new share. The Company is
focused on offering a range of medical devices and diagnostics.

On
December 13, 2010, pursuant to the terms of a share exchange agreement, the Company acquired 100% of the issued and outstanding
common stock of Eternity Healthcare Inc., a company incorporated under the laws of the Province of British Columbia on December
10, 2009 (“Eternity BC”), for 60,000,000 shares of its own common stock, which were distributed to the shareholders
of Eternity BC (the “Share Exchange Agreement”).

The
Share Exchange Agreement, which represents a majority of the then issued and outstanding shares of the Company, constituted a
change in control of the Company. The acquisition of Eternity BC was accounted for as a reverse acquisition in accordance with
Accounting Standards Codification (“ASC”) 805-40, “Business Combinations”. The Company determined for
accounting and reporting purposes that Eternity BC is the acquirer because of the significant holdings and influence of the control
group of the Company before and after the acquisition. As a result of the transaction, Eternity BC shareholders owned approximately
94.4% of issued and outstanding common stock of the Company on a diluted basis.

On
June 25, 2012, the Company entered into a marketing agreement with Mika Medical Company of Korea, to be the sole marketer of a
new line of needle-free injection product for North America. Furthermore, the marketing agreement was extended to some European
countries (Germany, France and Spain) in December 2012. Additionally, the Company obtained the rights to market the products throughout
the world with an Amendment dated December 20, 2012.

Since
signing the Distribution Agreement with Mika Medicals, the Company has emerged in organizational and start up activities, including
developing a new business plan, making arrangements for office space and raising additional capital. The Company is generating
revenue from product sales.

On
June 5, 2014 the Company registered to operate within the state of Arizona with the intention to take over operations within the
United States from the Canadian subsidiary. Beginning January 1, 2016 the Company took over operations within the United
States from Eternity Healthcare, Inc. (BC).

The
Company has net loss of $ 388,622 for the year ended April 30, 2016 (April 30, 2015 - $ 507,492) and has a working capital deficit
of $ 516,213 as at April 30, 2016 (April 30, 2015 - $ 117,164).

2.

Going concern

The
Company’s consolidated financial statements are prepared using generally accepted accounting principles in the United States
of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal
course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs
and allow it to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company
obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital,
it could be forced to cease operations. However, management is currently reviewing the possibility of partnering with,
merging with, or acquiring another medical device company with strong marketing abilities.

F-6

Eternity
Healthcare, Inc.

Notes
to the Consolidated Financial Statements

April
30, 2016 and 2015

(Expressed
in U.S. Dollars)

3.

Significant accounting policies

The
following is a summary of significant accounting policies used in the preparation of these consolidated financial statements.

Basis
of presentation

These
financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America
(“U.S. GAAP”) and are expressed in U.S. dollars.

Principles
of consolidation

The
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Eternity Healthcare Inc.
(BC). All significant intercompany balances and transactions have been eliminated in consolidation.

Cash
and cash equivalents

Cash
and cash equivalents include highly liquid investments with original maturities of three months or less.

Inventory

Inventory
is stated at the lower of cost or market with cost determined under the weighted average cost method.

Revenue

Revenue
is recognized at the point of sale and includes shipping revenue for delivery to the purchaser. Total revenues do not include
sales taxes as we serve as a pass-through conduit for collecting and remitting sales taxes. We recognize retail sales returns
as they occur as historical returns have been negligible. In accordance with SAB 104, revenue is recognized when (i) there is
persuasive evidence that an arrangement exists, (ii) delivery has occurred or service has been rendered, (iii) the price is fixed
or determinable, and (iv) collection is reasonably assured.

Foreign
currency translation

The
Company’s functional currency is the Canadian dollar and reporting currency is the U.S. dollar. All transactions initiated
in other currencies are translated into the reporting currency in accordance with ASC 830, “Foreign Currency Matters”
as follows:

iii)

Assets
and liabilities at the rate of exchange in effect at the balance sheet date; and

iv)

Revenue
and expense items at rate of exchange at the dates on which those elements are recognized.

At
April 30, 2016, 1 United States dollar was equal to 1.2536 Canadian dollars (April 30, 2015 - 1.2064).

The average exchange rate for the year ended April 30, 2016 was 1 United States dollar to 1.3163 Canadian dollars (April 30, 2015 - 1.1503).

Gains
and losses on translation are included in other comprehensive income (loss) in stockholders’ deficiency for the period.

Fair
value

The
carrying value of cash and cash equivalents, short-term investment, accounts receivable, accounts payable and due to related parties
approximate their fair values because of the short-term maturity of these financial instruments.

F-7

Eternity
Healthcare, Inc.

Notes
to the Consolidated Financial Statements

April
30, 2016 and 2015

(Expressed
in U.S. Dollars)

3.

Significant accounting policies - continued

Interest
rate risk

The
company is not exposed to significant interest rate risk due to the short-term maturity of its monetary assets and liabilities.

Credit
risk

Credit
risk is the risk of loss associated with counterparty’s inability to fulfill its payment obligations. The Company’s
credit risk is primarily attributable to cash and accounting receivable. Management believes that the credit risk concentration
with respect to financial instruments included in cash and accounts receivable is remote.

Currency
risk

The
Company’s operating expenses are primarily incurred in Canadian dollars, and fluctuation of the Canadian dollar in relation
to the United States dollar will have an impact upon the profitability of the Company and may also have an effect of the value
of the Company’s. The Company has not entered into any agreements or purchased any instruments to hedge possible currency
risk. At April 30, 2016 1 United States dollar was equal to 1.2536 Canadian dollars.

Basic
and diluted net income (loss) per share

The
Company computes net income (loss) per share in accordance with ASC 260, “Earnings per Share”. ASC 260 requires presentation
of both basic and diluted earnings per share (“EPS”) on the face of the income statement. Basic EPS is computed by
dividing net income (loss) available to common stockholders (numerator) by the weighted average number of shares outstanding (denominator)
during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury
stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price
for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants.
Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive.

Research
and development

The Company recognizes research and development costs in accordance with ASC 730, “Research and Development”, which requires the Company to expense research and development costs as they are incurred.

Income
taxes

Deferred
income taxes are reported for timing differences between items of income or expense reported in the financial statements and those
reported for income tax purposes in accordance with ASC 740, “Income Taxes”, which requires the use of the asset/liability
method of accounting for income taxes. Deferred income taxes and tax benefits are recognized for the future tax consequences attributable
to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases,
and for tax losses and credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Company
provides for deferred taxes for the estimated future tax effects attributable to temporary differences and carry-forwards when
realization is more likely than not.

F-8

Eternity
Healthcare, Inc.

Notes
to the Consolidated Financial Statements

April
30, 2016 and 2015

(Expressed
in U.S. Dollars)

3.

Significant accounting policies - continued

Comprehensive
loss

ASC
22, “Comprehensive Income”, establishes standards for the reporting and display of comprehensive loss and its components
in the financial statements. As at April 30, 2016, the Company has items that represent a comprehensive income (loss) and, therefore,
has included a schedule of comprehensive income (loss) in the financial statements.

Use
of estimates

The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect
the amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements
and the reported amounts of revenues and expenditures during the reporting period. Actual results could differ from these estimates.

Stock-based
compensation

Expenses
incurred as a result of stock-based compensation are recognized in accordance with ASC 718, “Compensation - Stock Compensation”.
Stock-based compensation expense (net of an estimated forfeiture rate) is recognized for those awards that are expected to vest
on a straight-line basis over the requisite service period. We estimate the forfeiture rate based on our historical experience
and expectations about future forfeitures. The fair value of stock options granted is estimated on the date granted using the
Black-Scholes pricing model.

Segments
of an enterprise and related information

ASC
280, “Segment Reporting” establishes guidance for the way that public companies report information about operating
segments in annual financial statements and requires reporting of selected information about operating segments in interim financial
statements issued to the public. It also establishes standards for disclosures regarding products and services, geographic areas
and major customers. ASC 280 defines operating segments as components of a company about which separate financial information
is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing
performance. The Company has evaluated this Codification and does not believe it is applicable at this time.

Recently
exacted accounting standards

Our
Company does not expect the adoption of any recently enacted accounting pronouncements to have a material impact on its financial
statements.

4.

Short-term investment

On
August 18, 2015 the Company invested $ 600,000 CAD ($ 459,000 USD) in One Year Cashable Guaranteed Investment Certificate (GIC)
term deposit. The investment has a one year tem that matures on August 18, 2016and bears interest at a rate of 0.672% per annum.

On
March 14, 2016 the Company withdrew $ 200,000 CAD ($ 150,000 USD) from the GIC and received interest of $ 770 CAD ($
576 USD). The remaining $ 400,000 CAD ($ 319,000 USD) continues to earn interest at a rate of 0.672% per annum. The
Company has recognized interest of $ 1,885 CAD ($ 1,504 USD) to April 30, 2016 with an additional $ 803 CAD anticipated
over the remaining term.

F-9

Eternity
Healthcare, Inc.

Notes
to the Consolidated Financial Statements

April
30, 2016 and 2015

(Expressed
in U.S. Dollars)

5.

Inventory

Inventory
consists of needle-free injection products that are held for resale. Inventory is stated at the lower of cost or market with cost
determined under the weighted average cost method. As of April 30, 2016 and April 30, 2015 inventory consisted of the following:

April 30,

April 30,

2016

2015

$

$

Raw Material

-

-

Work in progress

-

-

Finished goods

3,064

33,710

Reserve for obsolescence

-

-

3,064

33,710

6.

Accounts payable and accrued liabilities

Accounts
payable and accrued liabilities are non-interest bearing, unsecured and have settlement dates within one year.

7.

Due to related parties and related party transactions

During
the fiscal year ended April 30, 2016, the Company received $ 502,137 in additional cash loans from related parties of the Company
and made repayments to related parties of $ 471,459. Total related party notes payable as of April 30, 2016 were $ 977,887. Effective
November 1, 2014, this balance is interest bearing at 5% per year on the principle balance, unsecured and has no fixed terms of
repayment. During the year ended April 30, 2016 and 2015, the Company recorded interest expense of $ 48,918 and $ 21,624, respectively,
with regard to the outstanding related party loans.

8.

Capital stock

Authorized

The
total authorized capital is 300,000,000 common shares with a par value of $ 0.001 per common share.

On
October 6, 2014 the Company issued 130,000 common shares of the Company with a value of $ 9,100 for investor relations and business
services.

F-10

Eternity
Healthcare, Inc.

Notes
to the Consolidated Financial Statements

April
30, 2016 and 2015

(Expressed
in U.S. Dollars)

9.

Stock options

During
the fiscal year ended April 30, 2013, the Company granted 200,000 stock options for services. The fair value of the stock options
granted were estimated on the date granted using the Black-Scholes pricing model, with the following assumptions used for the
valuation: exercise price of $0.55 per share, average risk-free interest rate of 0.79%, expected dividend yield of zero, expected
lives of five years and an average expected volatility of 2.99%. During the fiscal year ended April 30, 2016 and 2015, the Company
recognized expense of $ Nil and $ 29,942 related to options that vested, respectively.

A
summary of the status of the Company’s stock options and warrants as of April 30, 2016 and changes during the years ended
April 30, 2016 and 2015 is presented below:

Number of

shares

Balance of stock options and warrants at April 30, 2014

200,000

Exercisable at April 30, 2013

129,040

Warrants and options granted

-

Exercised, forfeited or expired

-

Balance of stock options and warrants at April 30, 2015

200,000

Exercisable at April 30, 2015

200,000

Warrants and options granted

-

Exercised, forfeited or expired

-

Balance of stock option and warrants at April 30, 2016

200,000

Exercisable at April 30, 2016

200,000

Warrants and options granted

-

Exercised, forfeited or expired

-

The
following table summarizes information about the stock options and warrants as of April 30, 2016:

Option
and warrants

Options
and warrants

outstanding

exercisable

Weighted

Weighted

Weighted

average

average

average

Exercise

remaining

exercise

exercise

prices

Number

contractual

price

Number

price

$

outstanding

life
(in years)

$

exercisable

$

0.80

200,000

1.72

0.80

200,000

0.80

The
following table summarizes information about the stock options and warrants as of April 30, 2015:

Option
and warrants

Options
and warrants

outstanding

exercisable

Weighted

Weighted

Weighted

average

average

average

Exercise

remaining

exercise

exercise

prices

Number

contractual

price

Number

price

$

outstanding

life
(in years)

$

exercisable

$

0.80

200,000

2.96

0.80

200,000

0.80

F-11

Eternity
Healthcare, Inc.

Notes
to the Consolidated Financial Statements

April
30, 2016 and 2015

(Expressed
in U.S. Dollars)

10.

Income taxes

The
Company has losses carried forward for income tax purposes to April 30, 2016. There are no current or deferred tax expenses for
the year ended April 30, 2016 due to the Company’s loss position. The Company has fully reserved for any benefits of these
losses. The deferred tax consequences of temporary differences in reporting items for financial statement and income tax purposes
are recognized, as appropriate. Realization of the future tax benefits related to the deferred tax assets is dependent on many
factors, including the Company’s ability to generate taxable income within the net operating loss carryforward period. Management
has considered these factors in reaching its conclusion as to the valuation allowance for financial reporting purposes.

The
provisions for refundable federal income tax consist of the following:

April 30,

April 30,

2016

2015

$

$

Deferred tax assets attributable to:

Current operations

138,153

167,733

Non-deductible items

-

12,440

Change in tax rates

(585

)

(19

)

Change in valuation allowance

(137,568

)

(180,154

)

Net refundable amount

-

-

The
composition of the company’s deferred tax assets as at April 30, 2016 and April 30, 2015 is as follows:

April 30,

April 30,

2016

2015

$

$

Net operating loss carryforward

544,495

469,996

Equipment

144

157

Less: Valuation allowance

(544,639

)

(470,153

)

Net deferred tax asset

-

-

11.

Comparative figures

Certain
2015 figures have been reclassified to conform to the presentation adopted in the current year.

12.

Lease agreements

We
currently rent an office, warehouse, and assembly space of about 2,000 square feet at 8755 Ash Street, Suite 1, Vancouver, British
Columbia, Canada, V6P 6T3. Our office is also in the same location. Effective March 1, 2016, we are required to pay $2,705 CAD
plus applicable GST per month for rent. The original term of our lease was for a period of one year. We are currently renting
this space month-to-month.

13.

Subsequent events

In
accordance with ASC 855, the Company’s management has evaluated the subsequent events through the date the financial statements
were issued and has found no subsequent events to report.

F-12

Item
9.

Changes in and Disagreements With Accountants
on Accounting and Financial Disclosure

There
were no disagreements with our accountants related to accounting principles or practices, financial statement disclosure, internal
controls or auditing scope or procedure during the two fiscal years and subsequent interim periods.

Item
9A.

Controls and Procedures

Management’s
Report on Disclosure Controls and Procedures

Our
management, with the participation of our chief executive officer and chief financial officer (our principal executive
officer, principal financial officer and principal accounting officer), evaluated the effectiveness of our disclosure
controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934,
as amended (the “Exchange Act”)) as of the end of the period covered by this report. Based on this evaluation,
our chief executive officer and chief financial officer (our principal executive officer, principal financial officer and
principal accounting officer) concluded that, as of the end of such period, our disclosure controls and procedures were not
effective to ensure that information that is required to be disclosed by us in the reports we file or submit under the
Exchange Act is (i) recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules
and forms and (ii) accumulated and communicated to our management, including our chief executive officer and chief financial
officer (our principal executive officer, principal financial officer and principal accounting officer), as appropriate, to
allow timely decisions regarding required disclosure. The reasons for this finding were the weaknesses in our internal
control over financial reporting enumerated below.

Management’s
Annual Report on Internal Control over Financial Reporting

Our
management is responsible for establishing and maintaining adequate internal control over financial reporting. Our chief executive
officer and chief financial officer (our principal executive officer, principal financial officer and principal accounting officer)
conducted an evaluation of the effectiveness of our internal control over financial reporting as of April 30, 2016 using the criteria
established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway
Commission (COSO).

A
material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there
is a reasonable possibility that a material misstatement of our company’s annual or interim financial statements will not
be prevented or detected on a timely basis. In its assessment of the effectiveness of internal control over financial reporting
as of April 30, 2016, our company determined that there were control deficiencies that constituted material weaknesses, as described
below:

●

There
is a lack of accounting personnel with the requisite knowledge of Generally Accepted Accounting Principles in the US (“GAAP”)
and the financial reporting requirements of the Securities and Exchange Commission;

●

There
are insufficient written policies and procedures to ensure the correct application of accounting and financial reporting with
respect to the current requirements of GAAP and SEC disclosure requirements; and

●

There
is a lack of segregation of duties, in that we only had one person performing all accounting-related duties.

Notwithstanding
the existence of these material weaknesses in our internal control over financial reporting, our management believes that the
consolidated financial statements included in its reports fairly present in all material respects our company’s financial
condition, results of operations and cash flows for the periods presented.

Our
company will continue its assessment on a quarterly basis and as soon as we start operations we plan to hire personnel and resources
to address these material weaknesses. We believe these issues can be solved with hiring in-house accounting support and plan to
do so as soon as we have funds available for this. There has been no change in its internal control over financial reporting that
occurred during our company’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially
affect, our company’s internal control over financial reporting.

22

Changes
in Internal Controls

During
the period ended April 30, 2016, there were no changes in our internal control over financial reporting that materially affected,
or are reasonably likely to materially affect, our internal control over financial reporting.

Item
9B.

Other Information

None.

PART
III

Item
10.

Directors, Executive Officers and Corporate
Governance

All
directors of our company hold office until the next annual meeting of the security holders or until their successors have been
elected and qualified. The officers of our company are appointed by our board of directors and hold office until their death,
resignation or removal from office. Our directors and executive officers, their ages, positions held, and duration as such, are
as follows:

The
following is a brief account of the education and business experience during at least the past five years of each director, executive
officer and key employee of our company, indicating the person’s principal occupation during that period, and the name and
principal business of the organization in which such occupation and employment were carried out.

Hassan
Salari has acted as a director of our company since March 16, 2010. He was subsequently appointed as president and chief executive
officer on July 26, 2012 and as chief financial officer, treasurer and secretary on January 15, 2013. Hassan Salari is an entrepreneur
and scientist. Dr. Salari has over 30 years’ experience in the biotechnology field, specializing in highly sophisticated
research and drug development programs and business development.

Dr.
Salari was a director of Pacgen Biopharmaceuticals Inc., a public company with its shares listed on the TSX Venture Exchange.
From 1998 to 2007, Dr. Salari was chief executive officer and president of Chemokine Therapeutics Corp., a company established
as a focused biotechnology company to develop chemokine-based therapeutic products for human diseases. Chemokine was a public
company listed on OTC Bulletin Board and the TSX. From 1992 to 1998, Dr. Salari was a chief executive officer and president of
Inflazyme Pharmaceuticals Ltd., a company founded by Dr. Salari. Dr. Salari maintained the responsibility of managing the company’s
business affairs as well as its drug discovery and development programs (focused on allergies and asthma). While there, he negotiated
and closed several licensing deals with biotechnology and pharmaceutical companies.

23

We
appointed Dr. Salari as president, chief executive officer, chief financial officer, treasurer, secretary and as a member of our
company’s board of directors because of his experience with biotechnology and pharmaceutical companies.

Bin
Huang – Director

Bin
Huang was appointed as a director of our company on January 15, 2013. Bin Huang is a seasoned life-sciences executive with broad
experiences in general management, business development, financing and corporate governance in Canada and Asia.

From
2007 to December 2012, Mrs. Huang acted as president and chief executive officer of WEX Pharmaceuticals Inc. WEX is a subsidiary
of CK Life Sciences Int’l., (Holdings) Inc. (“CKLS”), listed on The Stock Exchange of Hong Kong Limited (stock
code: 0775). Mrs. Huang assisted WEX with completing a Canadian phase 3 trial of tetrodotoxin for cancer pain, conducted a US
phase 2 trial for chemotherapy-induced neuropathic pain, and completed a $35M financing in 2010. Mrs. Huang left WEX to join our
company.

Mrs.
Huang earned a Bachelors’ of Science Degree in Genetics from Wuhan University, China in 1978, a PhD in Cell Biology from
University of East Anglia, England in 1983 and a Masters of Business Administration Degree in 1994.

We
appointed Bin Huang as a member of our company’s board of directors because of her ability to raise capital and her knowledge
of the pharmaceutical industry.

Dominique
F. Borrelly – Director

Dominique
F. Borrelly was appointed as a director of our company on January 18, 2013. Mr. Borrelly has over 25 years of experience in sales
and marketing and corporate/business development in the pharmaceutical (at Ciba-Geigy/Novartis & Sanofi-Aventis) and biotech
sectors. Since 2000, he has been the president of Camargue Consulting, in Vancouver, British Columbia, Canada, wherein he specializes
in assisting start-up companies - from development, evaluation and in-licensing of new technologies, through initiation of strategic
alliances with multi-national corporate partners, to leading sales and marketing teams on commercial stage products.

In
2009, he was a healthcare network relationship specialist with Sanofi-Aventis Canada, Inc. in Vancouver, British Columbia, Canada,
wherein he developed and managed strategic partnerships with integrated healthcare networks, teaching hospitals and regional health
authorities in British Columbia.

From
2010 to 2012, Mr. Borrelly was a manager of the business development and acquisition division at Sanofi-Aventis Canada, Inc. in
Montreal, Quebec, Canada, wherein he maintained the business development and acquisition activities in healthcare services/e-health
solutions, oncology and diabetes (therapeutics and diagnostics) and medical devices.

We
appointed Dominique F. Borrelly as a member of our company’s board of directors because of extensive marketing and business
development experience the pharmaceutical and biotech sectors.

Family
Relationships

There
are no family relationships between any of the directors and officers.

24

Conflicts
of Interest

Our
directors are not obligated to commit their full time and attention to our business and, accordingly, they may encounter a conflict
of interest in allocating their time between our operations and those of other businesses. In the course of their other business
activities, they may become aware of investment and business opportunities which may be appropriate for presentation to us as
well as other entities to which they owe a fiduciary duty. As a result, they may have conflicts of interest in determining to
which entity a particular business opportunity should be presented. They may also in the future become affiliated with entities
that are engaged in business activities similar to those we intend to conduct.

In
general, officers and directors of a corporation are required to present business opportunities to the corporation if:

●

the
corporation could financially undertake the opportunity;

●

the
opportunity is within the corporation’s line of business; and

●

it
would be unfair to the corporation and its stockholders not to bring the opportunity to the attention of the corporation.

We
have adopted a code of ethics that obligates our directors, officers and employees to disclose potential conflicts of interest
and prohibits those persons from engaging in such transactions without our consent.

Involvement
in Certain Legal Proceedings

To
the best of our knowledge, none of our directors or executive officers has, during the past ten years:

1.

been
convicted in a criminal proceeding or been subject to a pending criminal proceeding (excluding traffic violations and other
minor offences);

2.

had
any bankruptcy petition filed by or against the business or property of the person, or of any partnership, corporation or
business association of which he was a general partner or executive officer, either at the time of the bankruptcy filing or
within two years prior to that time;

3.

been
subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction
or federal or state authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting, his involvement
in any type of business, securities, futures, commodities, investment, banking, savings and loan, or insurance activities,
or to be associated with persons engaged in any such activity;

4.

been
found by a court of competent jurisdiction in a civil action or by the SEC or the Commodity Futures Trading Commission to
have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;

5.

been
the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently
reversed, suspended or vacated (not including any settlement of a civil proceeding among private litigants), relating to an
alleged violation of any federal or state securities or commodities law or regulation, any law or regulation respecting financial
institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement
or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order, or
any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or

6.

been
the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory
organization (as defined in Section 3(a)(26) of the Exchange Act (15 U.S.C. 78c(a)(26))), any registered entity (as defined
in Section 1(a)(29) of the Commodity Exchange Act (7 U.S.C. 1(a)(29))), or any equivalent exchange, association, entity or
organization that has disciplinary authority over its members or persons associated with a member.

25

Compliance
with Section 16(a) of the Securities Exchange Act of 1934

Section
16(a) of the Securities Exchange Act of 1934 requires our executive officers and directors and persons who own more than 10% of
our common stock to file with the Securities and Exchange Commission initial statements of beneficial ownership, reports of changes
in ownership and annual reports concerning their ownership of our common stock and other equity securities, on Forms 3, 4 and
5 respectively. Executive officers, directors and greater than 10% shareholders are required by the SEC regulations to furnish
us with copies of all Section 16(a) reports that they file.

Based
solely on our review of the copies of such forms received by our company, or written representations from certain reporting persons
that no Form 5s were required for those persons, we believe that, during the fiscal year ended April 30, 2016, all filing requirements
applicable to our officers, directors and greater than 10% beneficial owners as well as our officers, directors and greater than
10% beneficial owners of our subsidiaries were complied with.

Code
of Ethics

We
have adopted a Code of Business Conduct and Ethics that applies to, among other persons, members of our board of directors, our
company's officers including our president, chief executive officer and chief financial officer, employees, consultants and advisors.
As adopted, our Code of Business Conduct and Ethics sets forth written standards that are designed to deter wrongdoing and to
promote:

1.

honest
and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional
relationships;

2.

full,
fair, accurate, timely, and understandable disclosure in reports and documents that we file with, or submit to, the Securities
and Exchange Commission and in other public communications made by us;

3.

compliance
with applicable governmental laws, rules and regulations;

4.

the
prompt internal reporting of violations of the Code of Business Conduct and Ethics to an appropriate person or persons identified
in the Code of Business Conduct and Ethics; and

5.

accountability
for adherence to the Code of Business Conduct and Ethics.

Our
Code of Business Conduct and Ethics requires, among other things, that all of our company's senior officers commit to timely,
accurate and consistent disclosure of information; that they maintain confidential information; and that they act with honesty
and integrity.

In
addition, our Code of Business Conduct and Ethics emphasizes that all employees, and particularly senior officers, have a responsibility
for maintaining financial integrity within our company, consistent with generally accepted accounting principles, and federal
and state securities laws. Any senior officer who becomes aware of any incidents involving financial or accounting manipulation
or other irregularities, whether by witnessing the incident or being told of it, must report it to our company. Any failure to
report such inappropriate or irregular conduct of others is to be treated as a severe disciplinary matter. It is against our company
policy to retaliate against any individual who reports in good faith the violation or potential violation of our company's Code
of Business Conduct and Ethics by another.

Our
Code of Business Conduct and Ethics was filed with the Securities and Exchange Commission as Exhibit 14.1 to our Annual Report
on Form 10-K for our year ended April 30, 2013. We will provide a copy of the Code of Business Conduct and Ethics to any person
without charge, upon request. Requests can be sent to: Eternity Healthcare Inc., 8755 Ash Street, Suite 1, Vancouver, BC V6P 6T3.

26

Board
and Committee Meetings

All
proceedings of our board of directors were conducted by resolutions consented to in writing by all the directors and filed with
the minutes of the proceedings of the directors. Such resolutions consented to in writing by the directors entitled to vote on
that resolution at a meeting of the directors are, according to the corporate laws of the state of Nevada and the bylaws of our
company, as valid and effective as if they had been passed at a meeting of the directors duly called and held.

Our
audit committee consists of our entire board of directors.

Our
company currently does not have nominating, compensation committees or committees performing similar functions nor does our company
have a written nominating, compensation or audit committee charter. Our board of directors does not believe that it is necessary
to have such committees because it believes that the functions of such committees can be adequately performed by our directors.

Our
company does not have any defined policy or procedure requirements for shareholders to submit recommendations or nominations for
directors. The directors believe that, given the early stage of our development, a specific nominating policy would be premature
and of little assistance until our business operations develop to a more advanced level. Our company does not currently have any
specific or minimum criteria for the election of nominees to the board of directors and we do not have any specific process or
procedure for evaluating such nominees. Our directors assess all candidates, whether submitted by management or shareholders,
and make recommendations for election or appointment.

A
shareholder who wishes to communicate with our board of directors may do so by directing a written request addressed to our president,
at the address appearing on the first page of this annual report.

Audit
Committee and Audit Committee Financial Expert

Our
board of directors has determined that none of the members of our audit committee qualifies as an “audit committee financial
expert” as defined in Item 407(d)(5)(ii) of Regulation S-K, and is “independent” as the term is used in Item
7(d)(3)(iv) of Schedule 14A under the Securities Exchange Act of 1934, as amended.

We
believe that the members of our board of directors are collectively capable of analyzing and evaluating our financial statements
and understanding internal controls and procedures for financial reporting. We believe that retaining an independent director
who would qualify as an "audit committee financial expert" would be overly costly and burdensome and is not warranted
in our circumstances given the early stages of our development and the fact that we have not generated any material revenues to
date. In addition, we currently do not have nominating, compensation or audit committees or committees performing similar functions
nor do we have a written nominating, compensation or audit committee charter. Our board of directors does not believe that it
is necessary to have such committees because it believes the functions of such committees can be adequately performed by our board
of directors.

Item
11.

Executive Compensation

The
particulars of the compensation paid to the following persons:

(a)

our
principal executive officer;

(b)

each
of our two most highly compensated executive officers who were serving as executive officers at the end of the years ended
April 30, 2016 and 2015; and

27

(c)

up
to two additional individuals for whom disclosure would have been provided under (b) but for the fact that the individual
was not serving as our executive officer at the end of the years ended April 30, 2016 and 2015,who
we will collectively refer to as the named executive officers of our company, are set out in the following summary compensation
table, except that no disclosure is provided for any named executive officer, other than our principal executive officers, whose
total compensation did not exceed $100,000 for the respective fiscal year:

Dr.
Hassan Salari was appointed as a director of our company on March 16, 2010 and as president and chief executive officer on
July 26, 2012 and as chief financial officer, treasurer and secretary on January 15, 2013.

Other
than as set out below, there are no arrangements or plans in which we provide pension, retirement or similar benefits for directors
or executive officers. Our directors and executive officers may receive share options at the discretion of our board of directors
in the future. We do not have any material bonus or profit sharing plans pursuant to which cash or non-cash compensation is or
may be paid to our directors or executive officers, except that share options may be granted at the discretion of our board of
directors.

Stock
Option Plan

On
January 15, 2013, our directors approved the adoption of the 2013 Stock Option Plan which permits our company to issue up to 6,300,000
shares of our common stock to directors, officers, employees and consultants of our company upon the exercise of stock options
granted under the 2013 Stock Option Plan.

Grants
of Plan-Based Awards

During
our fiscal year ended April 30, 2016 there were no grants of plan based awards to our named officers or directors.

28

Outstanding
Equity Awards at Fiscal Year End

The
particulars of unexercised options, stock that have not vested and equity incentive plan awards for our named executive officers
are set out in the following table:

Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Stock Rights That Have Not Vested (#)

Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($)

Bin Huang

100,000

Nil

-

0.80

January 15, 2018

-

-

-

-

Dominique F. Borrelly

100,000

Nil

-

0.80

January 18, 2018

-

-

-

-

Option
Exercises and Stock Vested

During
our fiscal year ended April 30, 2016 there were no options exercised by our named officers.

Compensation
of Directors

We
do not have any agreements for compensating our directors for their services in their capacity as directors, although such directors
are expected in the future to receive stock options to purchase shares of our common stock as awarded by our board of directors.

The
following table sets forth a summary of the compensation paid to our non-employee directors in 2016:

Bin
Huang was appointed as a director of our company on January 15, 2013.

(2)

Dominique
F. Borrelly was appointed as a director of our company on January 18, 2013.

We
have determined that we have two independent directors, Bin Huang and Dominique F. Borrelly, as that term is used in Item 7(d)(3)(iv)(B)
of Schedule 14A under the Securities Exchange Act of 1934, as amended, and as defined by Rule 4200(a)(15) of the NASDAQ
Marketplace Rules.

29

Pension,
Retirement or Similar Benefit Plans

There
are no arrangements or plans in which we provide pension, retirement or similar benefits for directors or executive officers.
We have no material bonus or profit sharing plans pursuant to which cash or non-cash compensation is or may be paid to our directors
or executive officers, except that stock options may be granted at the discretion of the board of directors or a committee thereof.

Indebtedness
of Directors, Senior Officers, Executive Officers and Other Management

None
of our directors or executive officers or any associate or affiliate of our company during the last two fiscal years, is or has
been indebted to our company by way of guarantee, support agreement, letter of credit or other similar agreement or understanding
currently outstanding.

The
following table sets forth, as of July 20, 2016, certain information with respect to the beneficial ownership of our common shares
by each shareholder known by us to be the beneficial owner of more than 5% of our common shares, as well as by each of our current
directors and executive officers as a group. Each person has sole voting and investment power with respect to the shares of common
stock, except as otherwise indicated. Beneficial ownership consists of a direct interest in the shares of common stock, except
as otherwise indicated.

Name and Address of Beneficial Owner

Amount
and Nature of

Beneficial Ownership (1)

Percentage of Class

Hassan Salari 1517 West 58 Avenue Vancouver BC V6P 6T3

34,771,588 Common

52.34%

Bin Huang 1199 Seymour Street, Suite 2407 Vancouver, BC V6B 1K3

75,000 Common (2)

*

Dominique F. Borrelly 1393 - 161B Street Surrey, BC V4A 7L7

155,000 Common (2)

*

Directors and Executive Officers as a Group

35,001,588 Common

52.57%

Francine Salari 1517 West 58 Avenue Vancouver BC V6P 6T3

19,000,005 Common

28.60%

Other Shareholders

19,000,005 Common

28.60%

*
Less than 1%.

(1)

Under
Rule 13d-3, a beneficial owner of a security includes any person who, directly or indirectly,
through any contract, arrangement, understanding, relationship, or otherwise has or shares:
(i) voting power, which includes the power to vote, or to direct the voting of shares;
and (ii) investment power, which includes the power to dispose or direct the disposition
of shares. Certain shares may be deemed to be beneficially owned by more than one person
(if, for example, persons share the power to vote or the power to dispose of the shares).
In addition, shares are deemed to be beneficially owned by a person if the person has
the right to acquire the shares (for example, upon exercise of an option) within 60 days
of the date as of which the information is provided. In computing the percentage ownership
of any person, the amount of shares outstanding is deemed to include the amount of shares
beneficially owned by such person (and only such person) by reason of these acquisition
rights. As a result, the percentage of outstanding shares of any person as shown in this
table does not necessarily reflect the person’s actual ownership or voting power
with respect to the number of shares of common stock actually outstanding on July 20,
2016. As of July 20, 2016, there were 66,429,868 shares of our company’s common
stock issued and outstanding.

(2)

Includes
options to acquire an aggregate of 75,000 shares of common stock by each of our directors,
Bin Huang and Dominique F. Borrelly, exercisable within 60 days.

30

Changes
in Control

We
are unaware of any contract or other arrangement or provisions of our Articles or Bylaws the operation of which may at a subsequent
date result in a change of control of our company. There are not any provisions in our Articles or Bylaws, the operation of which
would delay, defer, or prevent a change in control of our company.

Except
as disclosed herein, no director, executive officer, shareholder holding at least 5% of shares of our common stock, or any family
member thereof, had any material interest, direct or indirect, in any transaction, or proposed transaction since the year ended
April 30, 2016, in which the amount involved in the transaction exceeded or exceeds the lesser of $120,000 or one percent of the
average of our total assets at the year-end for the last three completed fiscal years.

As
at April 30, 2016, $977,887 is payable to a related party of our company related to operating expenses paid on behalf of our company
(April 30, 2015 –$921,227). This balance bears non-compounded interest at a rate of 5% per annum, is unsecured and has no
fixed terms of repayment.

Director
Independence

We
currently act with three directors, consisting of Hassan Salari, Bin Huang and Dominique F. Borrelly. We have determined that
we have two directors, Bin Huang and Dominique F. Borrelly, that qualify as “independent directors” as defined by
Nasdaq Marketplace Rule 4200(a)(15).

We
do not have a standing audit, compensation or nominating committee, but our entire board of directors acts in such capacities.
We believe that our board of directors is capable of analyzing and evaluating our financial statements and understanding internal
controls and procedures for financial reporting. The board of directors of our company does not believe that it is necessary to
have a standing audit, compensation or nominating committee because we believe that the functions of such committees can be adequately
performed by the board of directors. Additionally, we believe that retaining an independent director who would qualify as an “audit
committee financial expert” would be overly costly and burdensome and is not warranted in our circumstances given the early
stages of our development.

Item
14.

Principal Accounting Fees and Services

The
aggregate fees billed for the most recently completed fiscal year ended April 30, 2016 and for the fiscal year ended April 30,
2015 for professional services rendered by the principal accountant for the audit of our annual financial statements and review
of the financial statements included in our quarterly reports on Form 10-Q and services that are normally provided by the accountant
in connection with statutory and regulatory filings or engagements for these fiscal periods were as follows:

Year Ended

April 30,2016$

April 30, 2015

$

Audit Fees

12,500

12,500

Audit Related Fees

Nil

Nil

Tax Fees

Nil

Nil

All Other Fees

Nil

Nil

Total

12,500

12,500

Our
board of directors pre-approves all services provided by our independent auditors. All
of the above services and fees were reviewed and approved by the board of directors either
before or after the respective services were rendered.

Our
board of directors has considered the nature and amount of fees billed by our independent auditors and believes that the provision
of services for activities unrelated to the audit is compatible with maintaining our independent auditors’ independence.

31

PART
IV

Item
15.

Exhibits, Financial Statement Schedules

(a)

Financial
Statements

(1)

Financial
statements for our company are listed in the index under Item 8 of this document.

(2)

All
financial statement schedules are omitted because they are not applicable, not material
or the required information is shown in the financial statements or notes thereto.

Pursuant to the requirements of the
Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in
the capacities and on the dates indicated.

Site Links

Based on public records. Inadvertent errors are possible. Getfilings.com does not guarantee the accuracy or timeliness of any information on this site. Use at your own risk.
This website is not associated with the SEC.